VYGR +40%/AH on phase-1b data in PD: http://finance.yahoo.com/news/voyager-therapeutics-announces-positive-interim-210500272.html The procedure in question is gene therapy delivered via surgical implantation. VYGR held a CC this afternoon to discuss the data.